GlassScriptPhysician profile
Joseph Centofanti
NPI 1154360543
$23,755.53
in general payments reported to CMS, 2019-2025
39 companies · $2,018 in 2025
The $2,018 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $2,528 · 2021: $9,339 · 2022: $6,669 · 2023: $1,496 · 2024: $656 · 2025: $2,018.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,170 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,169.77 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $7,267.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $4,810.74 | 2022 | |
| Sk Life Science, INC. | $2,337.09 | 2020-2025 | Xcopri |
| Abbvie INC. | $1,386.44 | 2021-2025 | Ubrelvy, Qulipta, Duopa |
| Amgen INC. | $746.20 | 2019-2023 | Aimovig |
| Acadia Pharmaceuticals INC | $647.23 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $506.35 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $492.58 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $451.79 | 2019-2025 | Rytary, Ongentys, Lyvispah |
| Teva Pharmaceuticals USA, INC. | $444.76 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $360.02 | 2019-2023 | Nayzilam |
| Kyowa Kirin, INC. | $340.70 | 2019-2024 | Nourianz |
| Lundbeck LLC | $305.16 | 2021-2022 | |
| Neurelis, INC. | $294.06 | 2020-2025 | Valtoco |
| Acorda Therapeutics, INC | $283.52 | 2019-2023 | Inbrija |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Centofanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.